nach oben

Tumor Biology

Erschienen in:

13.11.2015 | Original Article

Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study

verfasst von: Ming-zhu Yin, Shu Tan, Xia Li, Yan Hou, Guosheng Cao, Kang Li, Junping Kou, Ge Lou

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Metabolites are the end products of cellular regulatory processes. Squamous cervical cancer (SCC) can alter the level of certain small molecular metabolite in plasma through modulating gene expression. In this study, we identified two metabolites, phosphatidylcholine (PC) and lysophosphatidylcholine (LPC), which are significantly down- and upregulated in plasma of SCC as compared to uterine fibroid (UF) patients via ultra-performance liquid chromatographic-mass spectrometry (UPLC-MS). In external prospective cohort, our assay has a sensitivity of 93.2 %, a specificity of 91.3 %, and an area under the receiver operating characteristic (ROC) curve (AUC) of 0.972. The level of LPC is significantly higher in SCC than in UF patients. An opposite result was observed in PC level. Our findings suggest that the PC and lysoPC could be used as novel biomarkers to facilitate SCC diagnosis.

Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181–9.CrossRefPubMed

Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–71.CrossRefPubMed

Welthagen W, Shellie R, Ristow M, Spranger J, Zimmermann R, Fiehn O. Comprehensive two dimensional gas chromatography-time of flight mass spectrometry, GCxGC-TOF for high resolution metabolomics: biomarker discovery on spleen tissue extracts of obese NZO compared to lean C57BL/6 mice. Metabolomics. 2005;1:57–65.CrossRef

Wang X, Sun H, Zhang A, Wang P, Han Y. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. J Sep Sci. 2011;34(24):3451–9. Review.CrossRefPubMed

Gouveia MJ, Brindley PJ, Santos LL, da Costa JM C, Gomes P, Vale N. Mass spectrometry techniques in the survey of steroid metabolites as potential disease biomarkers: a review. Metabolism. 2013;62(9):1206–17.CrossRefPubMedPubMedCentral

Odunsi K, Wollman RM, Ambrosome CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int J Cancer. 2005;113:782–8.CrossRefPubMed

Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 2010;16(23):5835–41.CrossRefPubMed

Abate-Shen C, Shen MM. Diagnostics. The prostate-cancer metabolome. Nature. 2009;457(7231):799–800.CrossRefPubMed

Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res. 2010;9(6):2988–95.CrossRefPubMed

10.

Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013;12(1):505–12.CrossRefPubMed

11.

Hou Y, Yin M, Sun F, Zhang T, Zhou X, Li H, et al. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol Biosyst. 2014;10(8):2126–33.CrossRefPubMed

12.

Yin M, Zhao F, Lou G, Zhang H, Sun M, Li C, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer. 2011;21(1):92–9.PubMed

13.

Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, et al. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012;105(2):206–11.CrossRefPubMed

14.

Rob L, Halaska M, Robova H. Nerve-sparing and individually tailored surgery for cervical cancer. Lancet Oncol. 2010;11(3):292–301. Review.CrossRefPubMed

15.

Lin HM, Barnett MP, Roy NC, Joyce NI, Zhu S, Armstrong K, et al. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn’s disease. J Proteome Res. 2010;9(4):1965–75.CrossRefPubMed

16.

Zhang J, Yan L, Chen W, Lin L, Song X, Yan X, et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta. 2009;650(1):16–22.CrossRefPubMed

17.

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMed

18.

Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37:603–10.CrossRef

19.

Smith CA, Maille OG, Want EJ, Qin C, Trauger SA, Brandon TR, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27:747–51.CrossRefPubMed

20.

Kjaer S, Hodall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66(21):10630–6.CrossRefPubMed

21.

Asaoka Y, Yoshida K, Sasaki Y, Nishizuka Y. Potential role of phospholipase A2 in HL-60 cell differentiation to macrophages induced by protein kinase C activation. Proc nat Acad Sci (Wash). 1993;90:4917–21.CrossRef

22.

Yoshida K, Asaoka Y, Nishizuka Y. Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids. Proc nat Acad Sci (Wash). 1992;89:6443–6.CrossRef

23.

Podo F. Tumour phospholipid metabolism. Review article. NMR Biomed. 1999;12:413–39.CrossRefPubMed

24.

Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Alfonso F. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Mol Imag Rev. 2007;3:123–37.CrossRef

25.

Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599–603.PubMed

26.

Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D’Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369–76.CrossRefPubMed

27.

Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm. 2006;3:496–506.CrossRefPubMed

28.

Lunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006;7:1109–23.CrossRef

29.

Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer. 1997;71(1):31–4.CrossRefPubMed

Titel: Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study
verfasst von: Ming-zhu Yin
Shu Tan
Xia Li
Yan Hou
Guosheng Cao
Kang Li
Junping Kou
Ge Lou
Publikationsdatum: 13.11.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4164-x

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma

Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma

miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition

Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance

TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma

STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie